Understanding and Overcoming Resistance to Selective FGFR Inhibitors across <i>FGFR2</i> -Driven Malignancies

Abstract

At progression to FGFR inhibitors, FGFR2-driven malignancies are characterized by high intra- and interpatient molecular heterogeneity, particularly in cholangiocarcinoma. Resistance to FGFR inhibitors can be overcome by sequential, molecularly oriented treatment strategies across FGFR2-driven tumors.